Updates are available Correction dated 2023-06-17
Click to view Correction: https://doi.org/10.1186/s13099-023-00555-y
-
Authors
Lin, Meng-Ju
Su, Tung-Hung
Chen, Chieh-Chang
Wu, Wei-Kai
Hsu, Shih-Jer
Tseng, Tai-Chung
Liao, Sih-Han
Hong, Chun-Ming
Yang, Hung-Chih
Liu, Chun-Jen
Wu, Ming-Shiang
Kao, Jia-Horng
-
Funding
Funding for this research was provided by:
National Taiwan University Hospital (110-N01, 111-L1005, 111-L1005, 111-L1005, VN-110-02)
National Science and Technology Council, Taiwan (MOST 109-2326-B-002-012-MY3)
Liver Disease Prevention & Treatment Research Foundation, Taiwan
- License Information
-
More Information
Article History
Received: 18 February 2023
Accepted: 25 April 2023
First Online: 22 May 2023
Change Date: 17 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13099-023-00555-y
Declarations
:
: This study was conducted in accordance with the ethical principles for medical research involving human subjects of the Declaration of Helsinki (updated version, 2013), and recommendations outlined in the International Conference on Harmonization guideline on Good Clinical Practice Guideline. Our study was approved by the Institutional Review Board of National Taiwan University Hospital (approval numbers: 201809039RIND and 201912040RINA). Written informed consent was obtained from all participants.
: Not applicable.
: T.-H. S. received research grant from Gilead Sciences, and was on speaker’s bureaus for Abbvie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda. J.-H. K. has served as a consultant for Abbvie, Gilead Sciences, Merck Sharp and Dohme, and Roche and on speaker’s bureaus for Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme. Others declare no conflict of interests.
